Multi-Region Brain Organoids (MRBOs)
A TechBio platform that pairs the most physiologically faithful human brain tissue with AI-driven computational genomics to generate proprietary CNS drug discovery insights no other system can produce.
The Problem
CNS drug development has the highest failure rate of any therapeutic area, and the root cause is computational, not just biological. AI models trained on 2D cell culture data or single-region organoids are learning from inputs that do not reflect human brain architecture. The predictions downstream inherit that poverty. Garbage in, garbage out, except here the garbage costs $2.6B per failed Phase III trial. 2D cultures and single-region organoids cannot generate the multi-regional connectivity signatures, neurovascular interaction data, or circuit-level functional readouts that would constrain an AI model to make clinically relevant predictions.
The field does not need another screening service. It needs a biological data engine that produces training data worthy of the AI models being built on top of it.
The Organotics Platform
Organotics sits at the intersection of advanced human tissue engineering and AI. The platform has two interlocking halves: a proprietary brain organoid system that generates the highest-fidelity human brain data available, and an AI/computational genomics engine that mines that data for drug targets, biomarkers, and predictive pharmacology.
The Biological Layer. Each MRBO integrates multiple brain regions (cortical, mid-hindbrain) with endothelial components into a single unified tissue, achieving ~80% transcriptomic fidelity to human fetal brain (validated by single-nucleus RNA-seq). This is the closest correlation among assessed multi-region organoid systems reported to date. The tissue spontaneously generates endogenous immune cells and early blood-brain barrier architecture via endothelial-hematopoietic transition, without exogenous co-culture. Every MRBO run produces structured, multi-modal datasets: transcriptomic, proteomic, electrophysiological, and imaging.
Key performance metrics:
- ~80% transcriptomic fidelity to human fetal brain
- Reproducible marker expression across batches (GAD65 ~82%, CTIP2 ~76%, overall mean ~68%)
- Functional neural network maturation with evolving spike frequency, burst dynamics, and network synchronization
- Patient-derivable from iPSCs for genotype-specific data generation at scale
The AI and Computational Genomics Layer. Led by world-class expertise in computational genomics and machine learning, this engine transforms raw MRBO-derived multi-omics into actionable intelligence. The computational pipeline performs:
- Automated cell-type deconvolution and trajectory inference from snRNA-seq across disease and perturbation conditions
- Multi-omic integration (transcriptomic, proteomic, electrophysiological) to build predictive models of drug response at cell-type resolution
- Iterative model refinement where each new MRBO dataset retrains and sharpens predictive accuracy
This is not AI applied retrospectively to someone else's data. The biological system and the computational system were designed together. The tissue generates the exact data types the AI models need, and the AI models inform which tissue experiments to run next. That closed loop is the core IP.
The Model
Organotics is not a CRO. We are a TechBio platform company that generates proprietary biological data from the most physiologically relevant human brain tissue available, layers AI and computational genomics on top, and partners with biopharma on CNS programs where that data creates a decisive advantage.
The business operates across three integrated layers:
1. Data Generation Platform. MRBOs produce high-content, multi-modal datasets from tissue with validated human fidelity. Each new disease model, perturbation screen, or patient-derived line adds to a growing proprietary data corpus that no competitor can replicate without rebuilding the tissue system from scratch.
2. AI Engine. Computational models mine the MRBO-derived corpus for target identification, mechanism-of-action deconvolution, biomarker discovery, and predictive pharmacology. The models get better with every program because they train on a continuously expanding, internally consistent dataset. This is the flywheel.
3. Pharma Partnerships. Programs are structured with biopharma partners around specific CNS indications. Organotics brings the platform, the proprietary data, and the computational layer. Partners bring clinical-stage molecules, therapeutic hypotheses, and pipeline priorities. Deals are structured with milestones and royalties, not hourly rates.
Disease Focus
The platform is purpose-built for CNS indications where circuit-level dysfunction and cell-type-specific vulnerability drive pathology:
- Neuropsychiatric disorders (schizophrenia, bipolar disorder, ASD, major depressive disorder)
- Neurodegenerative diseases (Alzheimer's, Parkinson's, ALS) with inflammatory and synaptic components
- Patient-specific MRBOs enable individualized disease modeling and drug-response profiling, creating a direct path to responder stratification and biomarker-driven clinical trial design.
Why This Compounds
Every partnership, every screen, every patient-derived line adds structured data to Organotics' proprietary corpus. The AI layer extracts more value from each new dataset because it learns from all prior datasets. More data feeds better models. Better models attract more partnerships. More partnerships generate more data. The platform becomes more valuable with every program it runs.
Most AI-driven drug discovery companies are computationally sophisticated but biologically dependent on public datasets or commoditized assays. Organotics owns both sides: the biological system that generates the data and the AI that extracts value from it. That vertical integration is the moat.
Publication
Kshirsagar A, Mnatsakanyan H, Kulkarni S, Guo J, Cheng K, Ofria LD, Bohra O, Sagar R, Mahairaki V, Badr CE, Kathuria A. Multi-Region Brain Organoids Integrating Cerebral, Mid-Hindbrain, and Endothelial Systems. Adv Sci (Weinh). 2025 Sep;12(33):e03768. doi: 10.1002/advs.202503768.
